Tafolecimab for high cholesterol: comparing dosing schedules
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a new injectable medicine, tafolecimab, that lowers LDL ('bad') cholesterol. It compares different dosing intervals to see how well they work when added to your current statin pill.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have high cholesterol and have been taking a stable dose of a statin pill (like atorvastatin, rosuvastatin, or simvastatin) for at least 4 weeks.
- Your LDL cholesterol is still above the target for your risk level (for example, if you have heart disease, your LDL is 1.8 mmol/L or higher).
- You have never taken a PCSK9 inhibitor (a class of injectable cholesterol drugs) before.
- You are willing to follow the study schedule and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well two cholesterol-lowering medicines, evolocumab and alirocumab, work in people with high cholesterol or heart disease. It reviews medical records from patients at a specific hospital to see how these medicines affect cholesterol levels.
This trial tests whether starting a new cholesterol-lowering injection early helps people who recently had a heart-related event and a procedure to open blocked arteries. It aims to reduce future heart problems.
This study tests whether giving a cholesterol-lowering injection (called a PCSK9 inhibitor) before a heart procedure to open blocked arteries can help people who are having a heart attack. The medicine may improve outcomes by lowering cholesterol quickly after the event.
This trial compares two very low LDL-cholesterol targets (below 1.0 vs 1.0-1.39 mmol/L) using extra medications (PCSK9 inhibitors) to see which is safer and better for people at extremely high risk of heart attacks or strokes.
This trial tests whether adding an intensive cholesterol-lowering drug (called a PCSK9 inhibitor) to standard care can reduce the risk of another stroke or heart attack in people who recently had a stroke from narrowed brain or neck arteries. It is a high-dose approach designed to rapidly lower cholesterol and may offer extra protection for those with high Lp(a).
This study tests a new injectable medication called HST101 for lowering cholesterol in people who are already taking cholesterol pills but still have high levels. It may help if you have heart disease or are at high risk.
Hear when a new Hyperlipidemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.